Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores
Journal of the National Cancer Institute — Barnes DR, Silvestri V, Leslie G, et al. | July 30, 2021
Following the development of recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS), researchers sought to evaluate the correlations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers. From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), 483 BRCA1 and 1,318 BRCA2 European ancestry male carriers were available. For male BRCA1 and BRCA2 carriers, population-based prostate and female breast cancer PRS are linked to a wide range of absolute breast and prostate cancer risks. Such findings call for additional research aimed at providing personalized cancer risks for male carriers and informing clinical management.